2021 Q1 Form 10-Q Financial Statement
#000156459021027549 Filed on May 13, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.780M | $2.980M |
| YoY Change | -6.71% | 7.97% |
| % of Gross Profit | ||
| Research & Development | $7.589M | $13.20M |
| YoY Change | -42.51% | 842.86% |
| % of Gross Profit | ||
| Depreciation & Amortization | $50.00K | $242.0K |
| YoY Change | -79.34% | -21.17% |
| % of Gross Profit | ||
| Operating Expenses | $10.41M | $16.24M |
| YoY Change | -35.87% | 1060.0% |
| Operating Profit | -$10.41M | |
| YoY Change | ||
| Interest Expense | -$593.0K | -$160.0K |
| YoY Change | 270.63% | 700.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $197.0K | $820.0K |
| YoY Change | -75.98% | -14.58% |
| Pretax Income | -$10.22M | -$15.42M |
| YoY Change | -33.73% | 27.32% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$10.22M | -$15.42M |
| YoY Change | -33.75% | 27.32% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$132.7K | -$268.8K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 54.24M | 50.84M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $192.7M | $105.0M |
| YoY Change | 83.52% | -0.19% |
| Cash & Equivalents | $55.98M | $34.52M |
| Short-Term Investments | $136.7M | $70.50M |
| Other Short-Term Assets | $600.0K | $900.0K |
| YoY Change | -33.33% | 12.5% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $194.8M | $107.4M |
| YoY Change | 81.3% | -0.05% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $100.0K | $294.0K |
| YoY Change | -65.99% | -82.71% |
| Goodwill | $0.00 | |
| YoY Change | -100.0% | |
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.000M | $1.306M |
| YoY Change | -23.43% | 18.73% |
| Total Long-Term Assets | $12.80M | $12.53M |
| YoY Change | 2.15% | -69.29% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $194.8M | $107.4M |
| Total Long-Term Assets | $12.80M | $12.53M |
| Total Assets | $207.6M | $120.0M |
| YoY Change | 73.04% | -19.1% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $2.700M | $1.227M |
| YoY Change | 120.05% | -64.94% |
| Accrued Expenses | $4.484M | $6.502M |
| YoY Change | -31.04% | 27.49% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | |
| YoY Change | ||
| Total Short-Term Liabilities | $7.207M | $7.729M |
| YoY Change | -6.75% | -13.16% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $25.24M | $24.70M |
| YoY Change | 2.2% | 0.0% |
| Other Long-Term Liabilities | $58.00K | $199.0K |
| YoY Change | -70.85% | -98.46% |
| Total Long-Term Liabilities | $25.30M | $199.0K |
| YoY Change | 12614.57% | -99.47% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $7.207M | $7.729M |
| Total Long-Term Liabilities | $25.30M | $199.0K |
| Total Liabilities | $32.51M | $32.66M |
| YoY Change | -0.46% | -29.77% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$267.7M | |
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $175.1M | $87.32M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $207.6M | $120.0M |
| YoY Change | 73.0% | -19.08% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$10.22M | -$15.42M |
| YoY Change | -33.75% | 27.32% |
| Depreciation, Depletion And Amortization | $50.00K | $242.0K |
| YoY Change | -79.34% | -21.17% |
| Cash From Operating Activities | -$9.597M | -$13.08M |
| YoY Change | -26.62% | 20.44% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $4.000K |
| YoY Change | -100.0% | -95.83% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$77.74M | $1.470M |
| YoY Change | -5388.44% | -80.19% |
| Cash From Investing Activities | -$77.74M | -$1.785M |
| YoY Change | 4255.13% | -124.39% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 120.5M | -466.0K |
| YoY Change | -25951.07% | -109.52% |
| NET CHANGE | ||
| Cash From Operating Activities | -9.597M | -13.08M |
| Cash From Investing Activities | -77.74M | -1.785M |
| Cash From Financing Activities | 120.5M | -466.0K |
| Net Change In Cash | 33.10M | -15.29M |
| YoY Change | -316.51% | -1215.99% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$9.597M | -$13.08M |
| Capital Expenditures | $0.00 | $4.000K |
| Free Cash Flow | -$9.597M | -$13.08M |
| YoY Change | -26.65% | 19.42% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7207000 | |
| CY2021Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
25244000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
25104000 | |
| CY2021Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
58000 | |
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
32509000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
64383000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
121827000 | |
| CY2021Q1 | svra |
Adjustment To Additional Paid In Capital Repurchase Of Pre Funded Warrants
AdjustmentToAdditionalPaidInCapitalRepurchaseOfPreFundedWarrants
|
3909000 | |
| CY2021Q1 | svra |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
2546000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
946000 | |
| CY2020Q1 | svra |
Tax Credit Income
TaxCreditIncome
|
821000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-431000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-128000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-26000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
17000 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10674000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-431000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-26000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
175121000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-10217000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-15421000 | |
| CY2021Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
47000 | |
| CY2020Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
58000 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
57000 | |
| CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
184000 | |
| CY2020Q1 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
5367000 | |
| CY2020Q1 | svra |
Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
|
2000 | |
| CY2021Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-57000 | |
| CY2020Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
156000 | |
| CY2021Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-161000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
69000 | |
| CY2021Q1 | svra |
Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
|
863000 | |
| CY2020Q1 | svra |
Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
|
821000 | |
| CY2021Q1 | svra |
Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
|
-781000 | |
| CY2020Q1 | svra |
Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
|
-3180000 | |
| CY2021Q1 | svra |
Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
|
-23000 | |
| CY2020Q1 | svra |
Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
|
-305000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9597000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13079000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
|
3247000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
94319000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
35614000 | |
| CY2021Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
16580000 | |
| CY2020Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
31300000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
5780000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-77739000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1785000 | |
| CY2021Q1 | us-gaap |
Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
|
3909000 | |
| CY2020Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
514000 | |
| CY2021Q1 | svra |
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
|
121827000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
48000 | |
| CY2021Q1 | svra |
Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants Net
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrantsNet
|
2546000 | |
| CY2021Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-28000 | |
| CY2020Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
41000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
33102000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-15289000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
22880000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
49804000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
55982000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
34515000 | |
| CY2020Q1 | svra |
Common Stock Issued For Acquired In Process Research And Development
CommonStockIssuedForAcquiredInProcessResearchAndDevelopment
|
-2120000 | |
| CY2021Q1 | svra |
Cash Paid For Interest Including End Of Period Charge Due Upon Debt Facility Amendment
CashPaidForInterestIncludingEndOfPeriodChargeDueUponDebtFacilityAmendment
|
484000 | |
| CY2020Q1 | svra |
Cash Paid For Interest Including End Of Period Charge Due Upon Debt Facility Amendment
CashPaidForInterestIncludingEndOfPeriodChargeDueUponDebtFacilityAmendment
|
990000 | |
| CY2021Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-267700000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9600000 | |
| CY2021Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
136700000 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management’s estimates include those related to the accrual of research and development and general and administrative costs, certain financial instruments recorded at fair value, contingent consideration, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates. </p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging instruments. The Company places its cash and cash equivalents with a limited number of high-quality financial institutions and at times may exceed the amount of insurance provided on such deposits. </p> | |
| CY2021Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2021Q1 | svra |
Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
|
996000 | |
| CY2020Q4 | svra |
Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
|
1042000 | |
| CY2021Q1 | svra |
Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
|
232000 | |
| CY2020Q4 | svra |
Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
|
591000 | |
| CY2021Q1 | us-gaap |
Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
|
427000 | |
| CY2020Q4 | us-gaap |
Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
|
653000 | |
| CY2021Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
213000 | |
| CY2020Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
453000 | |
| CY2021Q1 | svra |
Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
|
221000 | |
| CY2020Q4 | svra |
Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
|
194000 | |
| CY2021Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2089000 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2933000 | |
| CY2021Q1 | svra |
Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
|
2400000 | |
| CY2020Q4 | svra |
Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
|
2627000 | |
| CY2021Q1 | svra |
Accrued Compensation
AccruedCompensation
|
1069000 | |
| CY2020Q4 | svra |
Accrued Compensation
AccruedCompensation
|
1920000 | |
| CY2021Q1 | svra |
Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
|
876000 | |
| CY2020Q4 | svra |
Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
|
853000 | |
| CY2021Q1 | svra |
Accrued Lease Liability
AccruedLeaseLiability
|
139000 | |
| CY2020Q4 | svra |
Accrued Lease Liability
AccruedLeaseLiability
|
179000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4484000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5579000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
136757000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
6000 | |
| CY2021Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
32000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
136731000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
59307000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
4000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
59308000 | |
| CY2021Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | |
| CY2021Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
8333000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
8333000 | |
| CY2021Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
18167000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
18167000 | |
| CY2021Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
26500000 | |
| CY2020Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
26500000 | |
| CY2021Q1 | svra |
Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
|
1028000 | |
| CY2020Q4 | svra |
Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
|
1134000 | |
| CY2021Q1 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
129000 | |
| CY2020Q4 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
149000 | |
| CY2021Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
99000 | |
| CY2020Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
113000 | |
| CY2021Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
25244000 | |
| CY2020Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
25104000 | |
| CY2021Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
25244000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
25104000 | |
| CY2020Q4 | svra |
Upfront Cash Payment Payable
UpfrontCashPaymentPayable
|
3300000 | |
| CY2020 | svra |
Upfront Payment Common Stock Shares Issued
UpfrontPaymentCommonStockSharesIssued
|
1000000 | |
| CY2020 | svra |
Upfront Payment Common Stock Issued Value
UpfrontPaymentCommonStockIssuedValue
|
2100000 | |
| CY2020Q1 | svra |
Upfront Payment Research And Development Expense
UpfrontPaymentResearchAndDevelopmentExpense
|
5400000 | |
| CY2021Q1 | svra |
License Agreement Contingent Consideration Liability
LicenseAgreementContingentConsiderationLiability
|
0 | |
| CY2021Q1 | svra |
Decrease In Process Research And Development Due To Foreign Currency Translation
DecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
|
500000 | |
| CY2020Q1 | svra |
Decrease In Process Research And Development Due To Foreign Currency Translation
DecreaseInProcessResearchAndDevelopmentDueToForeignCurrencyTranslation
|
200000 | |
| CY2021Q1 | svra |
Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
|
129968000 | |
| CY2021Q1 | svra |
Public Offering Of Common Stock Offering Expenses
PublicOfferingOfCommonStockOfferingExpenses
|
8141000 | |
| CY2021Q1 | svra |
Net Proceeds After Deducting Underwriting Discounts Commissions And Offering Expenses
NetProceedsAfterDeductingUnderwritingDiscountsCommissionsAndOfferingExpenses
|
121827000 | |
| CY2021Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
48155491 | |
| CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
45133986 | |
| CY2021Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
42356273 | |
| CY2019Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-17000 | |
| CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
959000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
942000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-457000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
485000 | |
| CY2021Q1 | us-gaap |
Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
|
3192000 | |
| CY2021Q1 | svra |
Contingent Milestones Commitments Recognized
ContingentMilestonesCommitmentsRecognized
|
0 | |
| CY2021Q1 | svra |
Research And Development Expense For Termination
ResearchAndDevelopmentExpenseForTermination
|
800000 | |
| CY2021Q1 | svra |
Estimated Parexel Service Fees And Pass Through Expenses
EstimatedParexelServiceFeesAndPassThroughExpenses
|
31000000 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
946000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1194000 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9424782 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
37908150 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10217000 | |
| CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10217000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-15421000 | |
| CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-10217000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-15421000 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
76992407 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
57364265 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 |
